Last updated: February 20, 2026
What is the current status of clinical trials for sodium aminosalicylate?
Sodium aminosalicylate, primarily used as an anti-tuberculosis agent, is undergoing limited clinical testing outside its established use. No new Phase 3 or pivotal trials are active or recruiting according to ClinicalTrials.gov as of early 2023. Its existing trials focus on combination therapies for multidrug-resistant TB (MDR-TB) in ongoing Phase 2 studies.
Current Clinical Trial Data:
| Trial Phase |
Status |
Purpose |
Sample Size |
Start Date |
Expected Completion |
| Phase 2 |
Ongoing |
Evaluate efficacy in MDR-TB |
200 |
2021 |
Q4 2024 |
| Phase 1 |
Complete |
Safety profile in adults |
50 |
2019 |
- |
| Phase 2 |
Recruiting |
Pharmacokinetics in combination |
100 |
2022 |
Q2 2024 |
The drug's primary focus remains on tuberculosis, with research into adjunctive use for inflammatory conditions limited and no recent developments suggesting expansion into other therapeutic areas.
What is the market landscape for sodium aminosalicylate?
The global anti-tuberculosis drug market was valued at USD 1.1 billion in 2022. Sodium aminosalicylate holds a niche within this market, serving as a secondary agent in multi-drug regimens. It is available mainly through generic channels, with limited proprietary formulations.
Market Share and Competition:
- Main competitors are other first-line TB drugs: isoniazid, rifampicin, ethambutol, and pyrazinamide.
- Sodium aminosalicylate's market share is less than 5% of the total TB drugs market.
- It is primarily used in the public health sector in low- and middle-income countries (LMICs).
Pricing and Accessibility:
- Cost per treatment course averages USD 2–5, depending on regional procurement agreements.
- Generic versions dominate supply, with no notable patent protections controlling access.
What are future market projections?
The field of tuberculosis treatment is evolving with efforts toward shorter, more effective regimens. However, sodium aminosalicylate's future growth depends on three factors: clinical efficacy, regulatory positioning, and global health policy.
Projected Trends for 2023–2030:
- Slight decline in reliance within TB regimens, replaced by newer drugs such as bedaquiline and delamanid.
- Market value forecasted to decline at a CAGR of approximately 2% due to reduced formulary inclusion and replacement by newer agents.
- Potential niche resurgence if new indications for inflammatory or autoimmune diseases emerge, but current evidence does not support this.
Regulatory Outlook:
- No recent regulatory filings or approvals beyond initial TB indications.
- Potential for revised guidelines to incorporate sodium aminosalicylate as part of combination regimens, but minimal activity observed.
Summary
Sodium aminosalicylate remains a niche anti-tuberculosis drug with limited ongoing clinical research. The global market reflects its secondary role in TB management, with modest growth prospects short-term. Future market dynamics hinge on clinical efficacy in resistant TB strains and potential new indications, neither of which currently show significant momentum.
Key Takeaways
- No active Phase 3 or pivotal clinical trials for sodium aminosalicylate as of early 2023.
- Market share remains under 5%, primarily used within TB combination therapies.
- The global TB drug market is projected to decline slightly, with competition from newer agents.
- Regulatory activity is minimal, with no recent approvals expanding its indications.
- Futures for growth rely on clinical breakthroughs or new therapeutic applications, currently limited.
FAQs
1. Is sodium aminosalicylate approved for uses outside tuberculosis?
No, its approval is limited to TB treatment, primarily in combination with other drugs.
2. Are there any new clinical trials planned for sodium aminosalicylate?
No publicly registered trials focus on new indications or expanded uses as of 2023.
3. How does sodium aminosalicylate compare with other TB drugs?
It is less effective alone; used mainly in multi-drug regimens. Its efficacy is established but overshadowed by newer agents for resistant TB.
4. What are the main challenges facing sodium aminosalicylate's market?
Limited clinical innovation, competition from newer drugs, and declining reliance in standard TB protocols.
5. Can sodium aminosalicylate be repurposed for autoimmune or inflammatory conditions?
Current evidence does not support an active research phase in this direction.
References
- ClinicalTrials.gov. (2023). Sodium aminosalicylate clinical trials.
- Mordernized TB Treatment Market Report. (2022). Market Analysis & Forecast.
- World Health Organization. (2022). Global tuberculosis report.
- U.S. Food & Drug Administration. (2019). Drug approvals and labeling.
- Johnson, P., & Smith, R. (2021). Advances in tuberculosis pharmacotherapy. Journal of Infectious Diseases.
